J05AF05 • lamivudine • Antiinfectives for systemic use | Direct acting antivirals | Nucleoside and nucleotide reverse transcriptase inhibitors
Lamivudine is an antiviral drug used to treat human immunodeficiency virus (HIV) infection and chronic hepatitis B. It belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs) and works by blocking viral replication, preventing the virus from multiplying in the body.
It is used in combination therapy for HIV, helping to suppress viral load and maintain immune system function. In chronic hepatitis B, lamivudine can reduce liver inflammation and slow disease progression, although prolonged use may lead to viral resistance.
It is administered orally, once daily, and is well tolerated by most patients. Compared to other antivirals, it has a favorable safety profile, making it suitable for long-term use.
Side effects may include nausea, headache, fatigue, diarrhea, and, in rare cases, liver impairment or lactic acidosis. Regular monitoring is recommended to prevent the development of drug resistance.
Substance: lamivudine
Date of last drug list: 01-05-2024
Commercial code: W66004003
Concentration: 150mg
Pharmaceutical form: tablets
Quantity: 60
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: APL SWIFT SERVICES (MALTA) LIMITED - MALTA
Holder: AUROBINDO PHARMA ROMANIA S.R.L. - ROMANIA
Number: 10132/2017/03
Shelf life: 4 years